← All trials
NCT03982693
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 19, 2019
- Primary completion
- Dec 31, 2021
- Completion date
- Mar 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mt. Sinai Medical Center, MiamiLead sponsor
- Mt. Sinai Medical Center, MiamiOverall official - principal investigator
- Mt. Sinai Medical Center, MiamiReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.